These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 36283091)

  • 1. Evaluating new treatments for anaplastic thyroid cancer.
    Coca-Pelaz A; Rodrigo JP; Lopez F; Shah JP; Silver CE; Al Ghuzlan A; Menke-van der Houven van Oordt CW; Smallridge RC; Shaha AR; Angelos P; Mendenhall WM; Piazza C; Olsen KD; Corry J; Tufano RP; Sanabria A; Nuyts S; Nathan CA; Vander Poorten V; Dias FL; Suarez C; Saba NF; de Graaf P; Williams MD; Rinaldo A; Ferlito A
    Expert Rev Anticancer Ther; 2022 Nov; 22(11):1239-1247. PubMed ID: 36283091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case report: Complete response of an anaplastic thyroid carcinoma patient with
    Gui L; Zhu Y; Li X; He X; Ma T; Cai Y; Liu S
    Front Immunol; 2023; 14():1178682. PubMed ID: 37122752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination
    Gunda V; Ghosh C; Hu J; Zhang L; Zhang YQ; Shen M; Kebebew E
    Thyroid; 2023 Oct; 33(10):1201-1214. PubMed ID: 37675898
    [No Abstract]   [Full Text] [Related]  

  • 4. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.
    Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski CC; Cabanillas ME; Boran A; Ilankumaran P; Burgess P; Romero Salas T; Keam B
    Ann Oncol; 2022 Apr; 33(4):406-415. PubMed ID: 35026411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation based approaches to the treatment of anaplastic thyroid cancer.
    McCrary HC; Aoki J; Huang Y; Chadwick B; Kerrigan K; Witt B; Hunt JP; Abraham D
    Clin Endocrinol (Oxf); 2022 May; 96(5):734-742. PubMed ID: 35067961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma.
    Cabanillas ME; Ferrarotto R; Garden AS; Ahmed S; Busaidy NL; Dadu R; Williams MD; Skinner H; Gunn GB; Grosu H; Iyer P; Hofmann MC; Zafereo M
    Thyroid; 2018 Jul; 28(7):945-951. PubMed ID: 29742974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anaplastic thyroid carcinoma : new therapeutic approaches].
    Stamatiou A; Herrera-Gómez RG; Szturz P; Bisig B; Romano E; Sykiotis G; Gorostidi F; La Rosa S; Kopp P; Cristina V
    Rev Med Suisse; 2021 May; 17(739):962-966. PubMed ID: 34009754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease.
    Califano I; Smulever A; Jerkovich F; Pitoia F
    Rev Endocr Metab Disord; 2024 Feb; 25(1):123-147. PubMed ID: 37648897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer - Real-World Outcomes From UK Centres.
    Lorimer C; Cheng L; Chandler R; Garcez K; Gill V; Graham K; Grant W; Sardo Infirri S; Wadsley J; Wall L; Webber N; Wong KH; Newbold K
    Clin Oncol (R Coll Radiol); 2023 Jan; 35(1):e60-e66. PubMed ID: 36379836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement.
    Hamidi S; Dadu R; Zafereo ME; Ferrarotto R; Wang JR; Maniakas A; Gunn GB; Lee A; Spiotto MT; Iyer PC; Sousa LG; Akhave NS; Ahmed S; Learned KO; Lu C; Lai SY; Williams M; Hosseini SM; Busaidy NL; Cabanillas ME
    JAMA Oncol; 2024 Sep; 10(9):1264-1271. PubMed ID: 38990526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature.
    Arıkan R; Telli TA; Demircan NC; Başoğlu T; Ercelep Ö; Atasoy BM; Özgüven S; Dane F; Yumuk PF
    Curr Probl Cancer; 2021 Apr; 45(2):100668. PubMed ID: 33127167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer.
    Fazeli S; Paal E; Maxwell JH; Burman KD; Nylen ES; Khosla SG
    J Investig Med High Impact Case Rep; 2019; 7():2324709619890942. PubMed ID: 31766881
    [No Abstract]   [Full Text] [Related]  

  • 13. Acquired Secondary RAS Mutation in BRAF
    Cabanillas ME; Dadu R; Iyer P; Wanland KB; Busaidy NL; Ying A; Gule-Monroe M; Wang JR; Zafereo M; Hofmann MC
    Thyroid; 2020 Sep; 30(9):1288-1296. PubMed ID: 32216548
    [No Abstract]   [Full Text] [Related]  

  • 14. Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study.
    da Silva TN; Rodrigues R; Saramago A; Pires C; Rito M; Horta M; Martins C; Leite V; Cavaco BM
    Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36651156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anaplastic thyroid cancer:Improved understanding of what remains a deadly disease.
    Cleere EF; Prunty S; O'Neill JP
    Surgeon; 2024 Feb; 22(1):e48-e53. PubMed ID: 37866980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
    Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A
    Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laryngotracheal Resection After B-Raf Proto-oncogene Inhibition for Anaplastic Thyroid Carcinoma.
    Kent J; Erwin P; Haraf D; Liao CY; Durham J; Angelos P; Agrawal N; Baird BJ; Madariaga MLL
    Ann Thorac Surg; 2023 May; 115(5):e117-e120. PubMed ID: 35504360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in targeted therapy for anaplastic thyroid carcinoma.
    Qian C; Jiang L; Xu S; Wang J; Tan Z; Xin Y; Ge M
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 50(6):685-693. PubMed ID: 35347921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in
    Wang JR; Zafereo ME; Dadu R; Ferrarotto R; Busaidy NL; Lu C; Ahmed S; Gule-Monroe MK; Williams MD; Sturgis EM; Goepfert RP; Gross ND; Lai SY; Gunn GB; Phan J; Rosenthal DI; Fuller CD; Morrison WH; Iyer P; Cabanillas ME
    Thyroid; 2019 Aug; 29(8):1036-1043. PubMed ID: 31319771
    [No Abstract]   [Full Text] [Related]  

  • 20. The American Thyroid Association (ATA) integrates molecular testing into its framework for managing patients with anaplastic thyroid carcinoma (ATC): Update on the 2021 ATA ATC guidelines.
    Silver Karcioglu A; Iwata AJ; Pusztaszeri M; Abdelhamid Ahmed AH; Randolph GW
    Cancer Cytopathol; 2022 Mar; 130(3):174-180. PubMed ID: 34618407
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.